The observed increase in PRDM9 levels in mitotically arrested cells suggests that tumours treated with MTAs or drugs inducing mitotic arrest, such as Polo-like or Aurora kinase inhibitors, could upregulate PRDM9, enabling the emergence of persister cells and tumour recurrence. This evidence concerns the gene PRDM9 and neoplasm.